Jason Werner
Operationeel Directeur bij ALIMERA SCIENCES, INC.
Vermogen: 744 750 $ op 30-04-2024
Profiel
Jason M.
Werner is the founder of Eyevance Pharmaceuticals LLC, which was founded in 2017.
He held the title of Chief Operating Officer from 2017 to 2020.
He is currently the Director at InflammX Therapeutics, Inc. and the Chief Operating Officer at Alimera Sciences, Inc. since 2023.
Previously, he was the Chief Executive Officer at SightStream Biotherapeutics from 2021 to 2023 and the Chief Operating Officer at Eyevance Pharmaceuticals Holdings, Inc. from 2017 to 2020.
Mr. Werner obtained his undergraduate degree from the University of New Hampshire.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ALIMERA SCIENCES, INC.
0.43% | 11-03-2024 | 225 000 ( 0.43% ) | 744 750 $ | 30-04-2024 |
Actieve functies van Jason Werner
| Bedrijven | Functie | Begin |
|---|---|---|
| ALIMERA SCIENCES, INC. | Operationeel Directeur | 02-10-2023 |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Jason Werner
| Bedrijven | Functie | Einde |
|---|---|---|
SightStream Biotherapeutics
 SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Algemeen Directeur | 30-09-2023 |
Eyevance Pharmaceuticals LLC
 Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Oprichter | 01-09-2020 |
Eyevance Pharmaceuticals Holdings, Inc.
 Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Operationeel Directeur | 01-09-2020 |
Opleiding van Jason Werner
| University of New Hampshire | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ALIMERA SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Eyevance Pharmaceuticals LLC
Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Health Technology |
Eyevance Pharmaceuticals Holdings, Inc.
Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Health Technology |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
SightStream Biotherapeutics
SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Health Technology |
